Unknown

Dataset Information

0

The ?6 subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation.


ABSTRACT: Novel treatments against migraine are an urgent medical requirement. The ?6 subunit-containing GABAA receptors (?6GABAARs) are expressed in trigeminal ganglia (TG), the hub of the trigeminal vascular system (TGVS) that is involved in the pathogenesis of migraine. Here we reveal an unprecedented role of ?6GABAARs in ameliorating TGVS activation using several pharmacological approaches in an animal model mimicking pathological changes in migraine. TGVS activation was induced by intra-cisternal (i.c.) instillation of capsaicin in Wistar rats. Centrally, i.c. capsaicin activated the trigeminal cervical complex (TCC) measured by the increased number of c-Fos-immunoreactive (c-Fos-ir) TCC neurons. Peripherally, it elevated calcitonin gene-related peptide immunoreactivity (CGRP-ir) in TG and depleted CGRP-ir in the dura mater. Pharmacological approaches included a recently identified ?6GABAAR-selective positive allosteric modulator (PAM), the pyrazoloquinolinone Compound 6, two ?6GABAAR-active PAMs (Ro15-4513 and loreclezole), an ?6GABAAR-inactive benzodiazepine (diazepam), an ?6GABAAR-selective antagonist (furosemide), and a clinically effective antimigraine agent (topiramate). We examined effects of these compounds on both central and peripheral TGVS responses induced by i.c. capsaicin. Compound 6 (3-10?mg/kg, i.p.) significantly attenuated the TCC neuronal activation and TG CGRP-ir elevation, and dural CGRP depletion induced by capsaicin. All these effects of Compound 6 were mimicked by topiramate, Ro15-4513 and loreclezole, but not by diazepam. The brain-impermeable furosemide antagonized the peripheral, but not central, effects of Compound 6. These results suggest that the ?6GABAAR in TG is a novel drug target for TGVS activation and that ?6GABAAR-selective PAMs have the potential to be developed as a novel pharmacotherapy for migraine.

SUBMITTER: Fan PC 

PROVIDER: S-EPMC6180911 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

The α6 subunit-containing GABA<sub>A</sub> receptor: A novel drug target for inhibition of trigeminal activation.

Fan Pi-Chuan PC   Lai Tzu-Hsuan TH   Hor Chia Chun CC   Lee Ming Tatt MT   Huang Pokai P   Sieghart Werner W   Ernst Margot M   Knutson Daniel E DE   Cook James J   Chiou Lih-Chu LC  

Neuropharmacology 20180721


Novel treatments against migraine are an urgent medical requirement. The α6 subunit-containing GABA<sub>A</sub> receptors (α6GABA<sub>A</sub>Rs) are expressed in trigeminal ganglia (TG), the hub of the trigeminal vascular system (TGVS) that is involved in the pathogenesis of migraine. Here we reveal an unprecedented role of α6GABA<sub>A</sub>Rs in ameliorating TGVS activation using several pharmacological approaches in an animal model mimicking pathological changes in migraine. TGVS activation w  ...[more]

Similar Datasets

| S-EPMC2804419 | biostudies-literature
| S-EPMC2835428 | biostudies-other
| S-EPMC2911342 | biostudies-literature
| S-EPMC4060666 | biostudies-literature
| S-EPMC4950669 | biostudies-literature
| S-EPMC6089239 | biostudies-literature